5-Year Analysis of Phase III HIMALAYA Confirms Survival Benefit of STRIDE in ...
The HIMALAYA study's 5-year survival analysis shows 19.6% survival with STRIDE (durvalumab plus tremelimumab) vs 9.4% with sorafenib in unresectable hepatocellular carcinoma, with no new safety concerns.
Related Clinical Trials
Reference News
The HIMALAYA study's 5-year data showed tremelimumab plus durvalumab (STRIDE) improved overall survival (OS) in unresectable hepatocellular carcinoma (uHCC) patients compared to sorafenib, with a 5-year survival rate of 19.6% for STRIDE vs 9.4% for sorafenib. Disease control and any degree of tumor shrinkage were linked to long-term survival, with deep responses showing the greatest benefit.
The HIMALAYA study's 5-year survival analysis shows 19.6% survival with STRIDE (durvalumab plus tremelimumab) vs 9.4% with sorafenib in unresectable hepatocellular carcinoma, with no new safety concerns.